| Overview |
| bs-5234R-FITC |
| Bcl-xL (Thr115) Polyclonal Antibody, FITC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse |
| Rat, Dog, Cow, Sheep, Pig, Horse |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human BCL2L1 around the phosphorylation site of Thr115 |
| Thr115 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 598 |
| Q07817 |
| Cytoplasm, Nucleus, Cell membrane |
| BCLX; BCL2L; BCLXL; BCLXS; Bcl-X; bcl-xL; bcl-xS; PPP1R52; BCL-XL/S; Bcl-2-like protein 1; Bcl2-L-1; Apoptosis regulator Bcl-X; BCL2L1 |
| Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis. Isoform Bcl-X(L) also regulates presynaptic plasticity, including neurotransmitter release and recovery, number of axonal mitochondria as well as size and number of synaptic vesicle clusters. During synaptic stimulation, increases ATP availability from mitochondria through regulation of mitochondrial membrane ATP synthase F(1)F(0) activity and regulates endocytic vesicle retrieval in hippocampal neurons through association with DMN1L and stimulation of its GTPase activity in synaptic vesicles. Isoform Bcl-X(S) promotes apoptosis. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz